Cargando…
Manufacturing of convalescent plasma of COVID-19 patients: Aspects of quality
The ongoing coronavirus disease 2019 (COVID-19) pandemic emerged in December 2019. Convalescent plasma represents a promising COVID-19 treatment. Here, we report on the manufacturing of a plasma-based product containing antibodies specific to SARS-CoV-2 obtained from recently recovered COVID-19 pati...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755199/ https://www.ncbi.nlm.nih.gov/pubmed/33351831 http://dx.doi.org/10.1371/journal.pone.0243967 |
_version_ | 1783626313547907072 |
---|---|
author | Hähnel, Viola Peterhoff, David Bäuerlein, Veronika Brosig, Andreas-Michael Pamler, Irene Johnson, Christian Bica, Adelina Totir, Monica Ossner, Thomas Stemmer, Barbara Toelge, Martina Schütz, Anja Niller, Hans-Helmut Schmidt, Barbara Wagner, Ralf Gessner, André Burkhard, Ralph Offner, Robert |
author_facet | Hähnel, Viola Peterhoff, David Bäuerlein, Veronika Brosig, Andreas-Michael Pamler, Irene Johnson, Christian Bica, Adelina Totir, Monica Ossner, Thomas Stemmer, Barbara Toelge, Martina Schütz, Anja Niller, Hans-Helmut Schmidt, Barbara Wagner, Ralf Gessner, André Burkhard, Ralph Offner, Robert |
author_sort | Hähnel, Viola |
collection | PubMed |
description | The ongoing coronavirus disease 2019 (COVID-19) pandemic emerged in December 2019. Convalescent plasma represents a promising COVID-19 treatment. Here, we report on the manufacturing of a plasma-based product containing antibodies specific to SARS-CoV-2 obtained from recently recovered COVID-19 patients. Convalescent plasma donors were screened as follows: 1) previously confirmed SARS-CoV-2 infection (by real-time PCR (RT-PCR)); 2) a subsequent negative PCR test followed by a 2-week waiting period; 3) an additional negative PCR test prior to plasmapheresis; and 4) confirmation of the presence of SARS-CoV-2 specific antibodies. Convalescent plasma was stored fresh (2–6°C) for up to 5 days or frozen (-30°C) for long-term storage. Donor peripheral blood and final plasma product were assayed for binding antibodies targeting the SARS-CoV-2 S-protein receptor-binding domain (RBD) and their titers measured by an enzyme-linked immunosorbent assay (ELISA). We performed 72 plasmaphereses resulting in 248 final products. Convalescent plasma contained an RBD-specific antibody titer (IgG) ranging from 1:100 to 1:3200 (median 1:800). The titer was congruent to the titer of the blood (n = 34) before collection (1:100–1:6400, median 1:800). Levels of IL-8 and LBP of donors were slightly increased. Therapeutic products derived from a human origin must undergo rigorous testing to ensure uniform quality and patient safety. Whilst previous publications recommended RBD-specific binding antibody titers of ≥ 1:320, we selected a minimum titer of 1:800 in order to maximize antibody delivery. Production of highly standardized convalescent plasma was safe, feasible and was readily implemented in the treatment of severely ill COVID-19 patients. |
format | Online Article Text |
id | pubmed-7755199 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-77551992021-01-05 Manufacturing of convalescent plasma of COVID-19 patients: Aspects of quality Hähnel, Viola Peterhoff, David Bäuerlein, Veronika Brosig, Andreas-Michael Pamler, Irene Johnson, Christian Bica, Adelina Totir, Monica Ossner, Thomas Stemmer, Barbara Toelge, Martina Schütz, Anja Niller, Hans-Helmut Schmidt, Barbara Wagner, Ralf Gessner, André Burkhard, Ralph Offner, Robert PLoS One Research Article The ongoing coronavirus disease 2019 (COVID-19) pandemic emerged in December 2019. Convalescent plasma represents a promising COVID-19 treatment. Here, we report on the manufacturing of a plasma-based product containing antibodies specific to SARS-CoV-2 obtained from recently recovered COVID-19 patients. Convalescent plasma donors were screened as follows: 1) previously confirmed SARS-CoV-2 infection (by real-time PCR (RT-PCR)); 2) a subsequent negative PCR test followed by a 2-week waiting period; 3) an additional negative PCR test prior to plasmapheresis; and 4) confirmation of the presence of SARS-CoV-2 specific antibodies. Convalescent plasma was stored fresh (2–6°C) for up to 5 days or frozen (-30°C) for long-term storage. Donor peripheral blood and final plasma product were assayed for binding antibodies targeting the SARS-CoV-2 S-protein receptor-binding domain (RBD) and their titers measured by an enzyme-linked immunosorbent assay (ELISA). We performed 72 plasmaphereses resulting in 248 final products. Convalescent plasma contained an RBD-specific antibody titer (IgG) ranging from 1:100 to 1:3200 (median 1:800). The titer was congruent to the titer of the blood (n = 34) before collection (1:100–1:6400, median 1:800). Levels of IL-8 and LBP of donors were slightly increased. Therapeutic products derived from a human origin must undergo rigorous testing to ensure uniform quality and patient safety. Whilst previous publications recommended RBD-specific binding antibody titers of ≥ 1:320, we selected a minimum titer of 1:800 in order to maximize antibody delivery. Production of highly standardized convalescent plasma was safe, feasible and was readily implemented in the treatment of severely ill COVID-19 patients. Public Library of Science 2020-12-22 /pmc/articles/PMC7755199/ /pubmed/33351831 http://dx.doi.org/10.1371/journal.pone.0243967 Text en © 2020 Hähnel et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Hähnel, Viola Peterhoff, David Bäuerlein, Veronika Brosig, Andreas-Michael Pamler, Irene Johnson, Christian Bica, Adelina Totir, Monica Ossner, Thomas Stemmer, Barbara Toelge, Martina Schütz, Anja Niller, Hans-Helmut Schmidt, Barbara Wagner, Ralf Gessner, André Burkhard, Ralph Offner, Robert Manufacturing of convalescent plasma of COVID-19 patients: Aspects of quality |
title | Manufacturing of convalescent plasma of COVID-19 patients: Aspects of quality |
title_full | Manufacturing of convalescent plasma of COVID-19 patients: Aspects of quality |
title_fullStr | Manufacturing of convalescent plasma of COVID-19 patients: Aspects of quality |
title_full_unstemmed | Manufacturing of convalescent plasma of COVID-19 patients: Aspects of quality |
title_short | Manufacturing of convalescent plasma of COVID-19 patients: Aspects of quality |
title_sort | manufacturing of convalescent plasma of covid-19 patients: aspects of quality |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755199/ https://www.ncbi.nlm.nih.gov/pubmed/33351831 http://dx.doi.org/10.1371/journal.pone.0243967 |
work_keys_str_mv | AT hahnelviola manufacturingofconvalescentplasmaofcovid19patientsaspectsofquality AT peterhoffdavid manufacturingofconvalescentplasmaofcovid19patientsaspectsofquality AT bauerleinveronika manufacturingofconvalescentplasmaofcovid19patientsaspectsofquality AT brosigandreasmichael manufacturingofconvalescentplasmaofcovid19patientsaspectsofquality AT pamlerirene manufacturingofconvalescentplasmaofcovid19patientsaspectsofquality AT johnsonchristian manufacturingofconvalescentplasmaofcovid19patientsaspectsofquality AT bicaadelina manufacturingofconvalescentplasmaofcovid19patientsaspectsofquality AT totirmonica manufacturingofconvalescentplasmaofcovid19patientsaspectsofquality AT ossnerthomas manufacturingofconvalescentplasmaofcovid19patientsaspectsofquality AT stemmerbarbara manufacturingofconvalescentplasmaofcovid19patientsaspectsofquality AT toelgemartina manufacturingofconvalescentplasmaofcovid19patientsaspectsofquality AT schutzanja manufacturingofconvalescentplasmaofcovid19patientsaspectsofquality AT nillerhanshelmut manufacturingofconvalescentplasmaofcovid19patientsaspectsofquality AT schmidtbarbara manufacturingofconvalescentplasmaofcovid19patientsaspectsofquality AT wagnerralf manufacturingofconvalescentplasmaofcovid19patientsaspectsofquality AT gessnerandre manufacturingofconvalescentplasmaofcovid19patientsaspectsofquality AT burkhardralph manufacturingofconvalescentplasmaofcovid19patientsaspectsofquality AT offnerrobert manufacturingofconvalescentplasmaofcovid19patientsaspectsofquality |